new oral glp 1 agonist GLP-1 receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important issue is Daily Oral GLP-1 Receptor Agonist

Drug Trials Snapshots: DEFENCATH HOW TO USE THIS SNAPSHOT The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups

Heres the research physicians should know: Liew et al., 2014 (JAMA Pediatrics) risk ADHD/hyperkinetic disorders Brandlistuen et al., 2013 (IJE, MoBa Norway) Long-term use psychomotor & behavioral problems Avella-Garca et al., 2016 (IJE, Spain) ASD symptoms in boys, attention issues in both sexes Bornehag et al., 2018 (EHP, Sweden) Language delay in girls Ji et al., 2019 (JAMA Psychiatry) Cord blood biomarkers dose-response risk for ADHD & ASD Baker et al., 2020 (JAMA Pediatrics) Meconium biomarkers ADHD risk & altered brain connectivity Sznajder et al., 2022 (PLOS One) Use linked with neurobehavioral problems at 3 years Woodbury et al., 2024 (Pediatric Research / JDBP) Dose-response

Using low-quality forms: Don't be swayed by high milligram counts on cheap capsules

Delays gastric emptying, helping you feel fuller longer

However, the most important question still stands: Niacinamide vs Vitamin C: which one is better, and can you use them together